A San Diego-based startup biotech company founded by Andrew Young, M.D., Ph.D. utilizing a novel
therapeutic treatment for diabetes and obesity. A proof of concept human clinical trial began
in 2008 in the United Arab Emirates. The Series A financing was led by Mesa Verde Venture
Partners. Dan Wood is on the Board and is currently Acting CEO.
www.lineagen.com
A Utah-based biomarker discovery company focusing on novel, patentable diagnostic testing tools
and processes with a focus on the commercialization of diagnostics Autism, Multiple Sclerosis,
and COPD. A $5.8 million Series A round was led by Sanderling Ventures and vSpring Capital. Dan
Wood is a member of the LineaGen Board of Directors.
www.traversathera.com
A La Jolla, California-based biopharmaceutical company engaged in the discovery, development and commercialization of siRNA delivery technologies. The technology platform targets a wide variety of acute, chronic and infectious human diseases including programs for the treatment of glioma, metastatic ovarian cancer and AMD. Mesa Verde participated in the Series A and B financing. Dan Wood and Carey Ng are Board Observers.
www.elevationpharma.com
A San Diego-based specialty pharmaceutical company aimed at reformulation of an existing COPD drugs, delivered in a nebulized format. Mesa Verde participated in a note, convertible at a discount into the Series A round of financing. Dan Wood and Carey Ng are Board Observers.
www.medipacs.com
A Tucson, Arizona-based company developing advanced and innovative infusion pump technology for fluid delivery systems based upon electro-activated polymers.
Mesa Verde participated in the Series A financing. Dan Wood and Carey Ng are Board Observers.
www.biomatrica.com
A San Diego-based company that develops and offers innovative technologies that stabilize biological
materials at room temperature. Mesa Verde participated in the Series C financing as the company's
first institutional investor. Dan Wood and Carey Ng are Board Observers.
www.exagen.com
An Albuquerque based discovery driven, patient focused CLIA registered molecular diagnostics laboratory with a growing menu of proprietary, internally developed genomic tests to enable more accurate, efficient diagnosis and better disease management. Mesa Verde participated in the Series A financing. Dan Wood is a Board Observer.
Dan Wood Led Deals at IngleWood
Saves a life each day (NASDAQ-BEAT)
Best performing venture-backed IPO in the nation for 2008.Wireless heart monitoring
Raised largest private round in med-tech history
CEO chosen 2004 Entrepreneur of the Year in San Diego
Revenues: $135 million run rate / profitable
Dan Wood led 1st VC round, Board member for seven years
Novel cancer drug in phase II trials
Started in Arizona by Dan Von Hoff and Lawrence HurleyDan Wood led first VC round
Unique, innovative science leading to safer drugs
High potency for cancer and potentially, other diseases
In Phase II and Phase I Clinical Trials
Dan Wood was a Board Member for six years
Novel cancer drug in phase I trials, acquired by Biogen-Idec for $250 million
Technology from Sloan-KetteringNovel science with potential against many cancers
Strong Board, Scientific, Clinical Expertise and Investors
Two phase I programs; one late-stage
Dan Wood Board Observer for five years
www.cabrellis.com
Cabrellis Pharmaceuticals is a spin-out from Conforma Therapeutics and is also an oncology company. Cabrellis was acquired for $104 million by Pharmion in November, 2006.
Novel heart imaging device (NASDAQ-DRAD)
Heart imaging by novel SPECT technologyJune 2004 IPO
Approximately $75 million in annual sales
Dan Wood was Board Observer for 3.5 years
